Huisheng Biopharmaceutical and Tonghua Dongbao Achieve Exclusive Commercial Cooperation; Two Main Insulin Products Accelerate Nationwide Market Expansion
Recently, Huisheng Biopharmaceutical Co., Ltd. (a non-wholly owned subsidiary of Sihuan Pharmaceutical Holdings Group Ltd. (Stock Code: 00460.HK), hereinafter referred to as "Huisheng Biopharmaceutical") and Tonghua Dongbao Pharmaceutical Co., Ltd. (Stock Code: 600867.SH, hereinafter referred to as “Tonghua Dongbao” or "Dongbao Pharmaceutical") officially signed the Commercialization Cooperation Agreement. Huisheng Biopharmaceutical granted Dongbao Pharmaceutical the exclusive commercialization rights for two of its key diabetes drugs in mainland China: Insulin Degludec and Insulin Aspart Injection (brand name: Huiyoujia) and Insulin Degludec Injection (brand name: Huiyouda). Leveraging Tonghua Dongbao's mature commercialization network and market coverage capabilities in the diabetes field, to fully accelerate the market promotion and patient access of these two core products, achieving the large-scale implementation of domestically produced high-quality glucose-lowering drugs.
The two products authorized in this collaboration are Huisheng Biopharmaceutical's core blockbuster products in the diabetes treatment field. Among them, Insulin Degludec and Insulin Aspart Injection is a new-generation soluble dual-insulin preparation, and Insulin Degludec Injection is a new-generation long-acting basal insulin. Both of them are the first biosimilars drugs approved for marketing in China. According to Novo Nordisk's 2025 annual report, the combined revenue of the two imported products with the same generic names in Greater China reached approximately RMB 4.3 billion, demonstrating broad market space and growth potential. With the continuous improvement of domestic production levels and drug accessibility, these products are expected to further enhance domestic basal insulin treatment protocols and drive the iterative upgrade of integrated basal and mealtime complex insulin therapy solutions that are more aligned with the dietary structure of the Chinese population.
As the core innovation platform for Sihuan Pharmaceutical's diabetes and endocrinology sector, the rapid development and continuous delivery of core products by Huisheng Biopharmaceutical rely on Sihuan Pharmaceutical's comprehensive strategic guidance and resource empowerment. Sihuan Pharmaceutical adheres to innovation as its core driving force. Supported by its independent R&D technology platforms, project management capabilities, full-dosage-form production capacity, and mature commercialization system, it continues to strengthen its "two-wheel drive strategy of medical aesthetics and biopharmaceutical businesses," providing solid support for its business segments. Living up to expectations, Huisheng Biopharmaceutical itself, after more than ten years of deep cultivation, has become one of the few domestic biopharmaceutical companies achieving full product coverage in diabetes and its complications, integrating R&D, production, and sales across the entire industrial chain. The company has gathered experienced R&D talent, with a pipeline of over 30 products in development and approved, covering third-generation and new types of insulin, SGLT-2 inhibitors, GLP-1 receptor agonists, and other latest-mechanism products, forming a tiered and diversified product portfolio.
Through this collaboration, Huisheng Biopharmaceutical will leverage Dongbao Pharmaceutical's extensive and efficient commercialization system and brand advantages in the diabetes field to accelerate the market promotion and clinical application of Huiyoujia and Huiyouda, to rapidly increase product market penetration and brand influence, further releasing the market value of domestically innovated glucose-lowering drugs. Simultaneously, the two products will also create synergistic effects with Dongbao's existing diabetes treatment products, enhancing its product matrix in the endocrinology and metabolism field. Both parties will take this cooperation as an opportunity to promote wider access of high-quality domestic insulin products to patient groups, help continuously improve China's diabetes prevention and treatment standards, and achieve mutual benefit, win-win outcomes, and high-quality development.
About Dongbao Pharmaceutical
Dongbao Pharmaceutical is a renowned domestic pharmaceutical company integrating drug R&D, production, and sales. The company is deeply engaged in the diabetes treatment field and possesses the most comprehensive and abundant diabetes treatment product R&D pipelines. Concurrently, the company is actively advancing into first-in-class innovative drugs in other endocrinology fields such as weight loss and gout/hyperuricemia. Its existing product portfolio mainly includes human insulin, insulin glargine, insulin aspart, liraglutide injection, Zhen Naoning capsules, and diabetes-related medical devices. Its pipeline includes products such as ultra-rapid-acting insulin, semaglutide, GLP-1/GIP dual-target receptor agonists, small molecule GLP-1 receptor agonists, and XO/URAT1 dual-target inhibitors.
About Huisheng Biopharmaceutical
Huisheng Biopharmaceutical is a biopharmaceutical company focusing on the field of diabetes and its complications under Sihuan Pharmaceutical, a large domestic pharmaceutical and medical aesthetics group. After ten years of construction and development, Huisheng Biopharmaceutical has become a fully integrated biopharmaceutical company with complete product coverage in diabetes and its complications, integrating R&D, production, and sales. The company has an R&D team with rich experience in diabetes drug development. Its pipeline contains over 30 products under development or approved, covering third-generation and new types of insulin (including basal, premixed, and rapid-acting products), SGLT-2 inhibitors, GLP-1 receptor agonists, other latest-mechanism products, and various commonly used glucose-lowering and complication treatment drugs. Huisheng Biopharmaceutical is committed to providing comprehensive, full-process, integrated therapeutic solutions for diabetes patients, serving a wide patient population.
About Sihuan Pharmaceutical
Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international pharmaceutical and medical aesthetics enterprise driven by innovation. It possesses independent and leading proprietary R&D technology platforms, a rich global product pipeline, strong product registration capabilities, a full dosage form production platform with highly efficient and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.
Sihuan Pharmaceutical Investor Relations Department